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A Comparison of Various Monoclonal Antibodies to the Previous Standard of
Care Chemotherapy in the Treatment of Advanced-Stage Melanoma
Abstract
In the year 2015, it is estimated that the number of new cases of invasive melanoma will be 42,670 in males
and 31,200 in females.1 Melanoma is treatable with early diagnosis; however, more advanced disease has
devastating outcomes. For the past decade, two chemotherapy agents, dacarbazine and temozolomide,
have been the treatment of choice for advanced stage III or IV melanoma requiring systemic treatment.
Interleukin-2 (IL-2) therapy has been used but with serious side effects. More recently, the focus has shifted
to monoclonal antibodies and enzyme inhibitors as the main systemic treatment for advanced cutaneous
melanoma. This literature review gathered several studies which looked at the use of monoclonal
antibodies, and compared monoclonal antibodies to conventional chemotherapy to assess whether there
is a significant difference in tumor response, sustained remissions and side effect profile. An extensive
medical literature review was conducted with PubMed and Cochrane databases using the keywords:
“monoclonal antibody,” “melanoma,” and “treatment.” This list of articles was further narrowed by specific
inclusion and exclusion criteria as well as reviewed for validity and quality using the GRADE system. Seven
clinical trials were included in this literature review. One observational study evaluated the overall safety
and efficacy of monoclonal antibodies, while another compared monoclonal antibodies versus placebo
under the same variables. Three of the research studies were randomized clinical trials evaluating the
safety and efficacy of monoclonal antibodies in comparison to chemotherapy. Two retrospective studies
assessed patients from expanded access programs who did not meet criteria to participate in a clinical
trial. All seven studies had similar inclusion and exclusion criteria and the patients were prognostically
similar before starting treatment. Six out of the seven studies demonstrated superiority of monoclonal
antibodies advanced-stage melanoma treatment. One study failed to demonstrate a statistically significant
survival advantage over traditional chemotherapy. The use of monoclonal antibodies has been
demonstrated to be a more specific and effective treatment approach than other therapies tried in the
past. While monoclonal antibodies have demonstrated efficacy in first line treatment for advanced stage
melanoma, further research is necessary to determine which combination of medications is most
beneficial for these patients.
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A Literature Review of the Comparison of Various Monoclonal Antibodies to the Previous Standard of Care
Chemotherapy
in the Treatment of Advanced-Stage Melanoma
BACKGROUND
The American Cancer Society estimates that in 2012 there were 14.1 million new diagnoses of cancer made
worldwide. Out of the 14.1 million new cases, 8.2 million succumbed to their disease. 1 Cancers of the skin are the most
common.2 Melanoma, a cancer of the skin cells called melanocytes, accounts for only 2% of these skin cancers, but
causes the majority of skin cancer deaths. In 2015, it is estimated that 73,870 new melanoma diagnoses will be made,
and 9,940 of those patients will pass away.2
Melanoma is staged in a four-tier system. Each stage has one to three sub-stages. Generally, the 5 and 10 year
survival rate decreases as the stages increase, the one exception being stage IIC versus stage IIIA and IIIB. 3 The 5
year survival rate for a patient with stage I disease is 97% compared to the 5 year survival rate for a patient with stage
IV disease, which is 15% to 20%.3 With this drastic difference in the death rate between stage I and IV, it is imperative
that clinicians take a look at treatment options, especially those available to patients with advanced-stage disease.
The treatment for malignant melanoma is dependent on the stage of disease. Generally, in early disease states and
patients with limited metastases, surgical resection is the treatment of choice. If diagnosed early, surgery is often
curative. Once the cancer reaches stage IV, surgery is no longer an immediate and definitive option, and as a result
the majority of patients require systemic therapy. The history of systemic therapy for advanced cutaneous melanoma is
disappointing. The treatments available have not been demonstrated to provide patients with a lasting remission, and
many of the side effects were toxic and often times unbearable.
Two chemotherapeutic drugs, dacarbazine and temozolomide, were the predominant go-to systemic treatment for
patients with metastatic melanoma in the past. Dacarbazine is considered to be the most active single-agent
chemotherapy for patients with advanced melanoma. The response rate is anywhere between 8% to 20%, but none of
the responses are complete and lasting.4 Temozolomide is an analog of dacarbazine. Unlike dacarbazine,
temozolomide is absorbed orally and crosses the blood brain barrier, so it was thought to have better response rates
than dacarbazine.5 When compared directly to dacarbazine, temozolomide shows no significant improvements in
overall survival.6
High-dose interleukin-2 (IL-2) was the first immunotherapy used for advanced stage melanoma which provided patients
with a durable remission.7 Interleukin-2 is a T-cell growth factor that was discovered in the late 1970s. After its
discovery, it was widely used as a treatment for advanced-stage cancers of multiple origins, and especially those who
failed first line treatment options. It soon became the drug of choice in advanced-stage melanoma treatment. Although
this was the first treatment discovered that demonstrated a significant response for patients with stage IV melanoma, it
came with significant drawbacks. IL-2’s severe multi-organ toxicity limited the number and type of patients who were
approved to use the treatment. IL-2 also requires that treatment, if given, must be administered by specific physicians
at hospitals equipped to handle the potential side effects. In addition, the same efficacy was not seen in patients who
used IL-2 after previous systemic therapy. As a result, many patients were forced to use cytotoxic chemotherapy,
which demonstrates no clinical benefit and only provides palliative care.
As a result of the limited use of IL-2 and the poor response to cytotoxic chemotherapy, more treatment options have
been sought for advanced-stage melanoma. Targeted therapies using monoclonal antibodies and enzyme inhibitors
have now made their way to the forefront of systemic treatment for advanced cutaneous melanoma. Monoclonal
antibodies are antibodies that are directed towards specific receptors and ligands on the surface of cells, which when
binding, prevent cellular activation. Enzyme inhibitors are molecules that bind directly to specific enzymes which then
act as competitive inhibitors of ATP binding.9 These treatments, when used alone or in combination with one another or
chemotherapy, provide patients with a treatment approach that is much more precise than previous treatments were
able to accomplish in the past, and are said to be more tolerable than previous therapy with cytotoxic chemotherapy
and/or IL-2.
In the case of melanoma treatment, there are 4 pathways that are targeted with immunotherapy: checkpoint inhibition
with the anti-PD1 antibody (pembrolizumab, nivolumab), checkpoint inhibition with the anti-CTLA4 antibody
(ipilimumab), BRAF gene inhibition (vemurafenib, dabrafenib) and MEK gene inhibition (trametinib, cobimetinib).
Checkpoint inhibition with the anti-PD1 antibody used in combination with the CTLA-4 antibody is now the preferred

treatment for advanced stage melanoma.8 The purpose of this literature review is to compare various monoclonal
antibodies when used alone, to the previous standard of care chemotherapy to see if there is a difference in tumor
response, durable remissions and patient tolerability.
METHODS
The PubMed and Cochrane databases were searched using the keywords “monoclonal antibody,” “melanoma,” and
“treatment.” PubMed yielded 2,835 articles and Cochrane yielded 33 results. Articles written within the last 5 years
were extracted for further review. Titles and abstracts were read for relevance and articles discussing the efficacy and
safety of monoclonal antibody use in the treatment of melanoma and those comparing the use of monoclonal antibody
therapy with standard chemotherapy were further reviewed. Twenty articles from PubMed’s database and 5 articles
from Cochrane’s database were eligible for more extensive review. These 25 articles were read in more detail to
ensure that they met the following inclusion/exclusion criteria.
Inclusion Criteria
1.
Articles written in English.
2.
Articles published between 2010 and 2015.
3.
Clinical trials evaluating the safety and efficacy of monoclonal antibodies as treatment for Stage III
melanoma, Stage IV melanoma, and recurrent melanoma.
4.
Clinical trials evaluating the safety and efficacy of monoclonal antibodies directly compared with standard
chemotherapy.
5.
Retrospective studies specifically published after evaluation of use of monoclonal antibodies in treatment of
melanoma as part of an expanded access program (EAP) to evaluate the use of this treatment option in a
typical clinical setting.
Exclusion Criteria
1.
Articles written before 2010.
2.
Articles written in a language other than English.
3.
Clinical trials completed in non-human subjects.
4.
Clinical trials where monoclonal antibodies were used in combination with other drugs.
5.
Case studies.
6.
Trials evaluating ranges of dosing for treatment.
7.
Retrospective studies that were not conducted as part of an expanded access program (EAP).
8.
Literature Reviews.
9.
Clinical trials that evaluated the use of monoclonal antibodies for treatment of cancers other than melanoma.
RESULTS
Twenty-five articles were reviewed and evaluated based on our inclusion/exclusion criteria and standard critical
appraisal guideline (CASP). Only articles discussing clinical trials and retrospective studies conducted with expanded
access programs were included. Seven articles met our criteria for inclusion into this review. Four of the articles
discuss the safety and efficacy of specific drugs within the class of monoclonal antibodies. The other 3 articles directly
compared the efficacy of a drug within the class of monoclonal antibodies to the standard chemotherapy of choice.
Articles were evaluated using the GRADE criteria for validity and quality.

Table 1. GRADE Profile
Author

Participants
(Studies)

Risk of
Bias

Inconsistency

Indirectness

Imprecision

Publication
Bias

Kirkwood et al

251 (OS)a

Seriousb

Not Serious

Not Serious

Not Serious

None

951 (RCT)

Seriousc

Not Serious

Not Serious

Not Serious

None

74 (OS)a

Seriousd

Not Serious

Not Serious

Not Serious

None

Not Serious

Not Serious

Seriouse

None

Not Seriousf

Not Serious

Not Serious

None

Eggermont et
al
Altomonte et
al
Di Giacomo et
al

27 (OS)a

Not
Serious
Not
Serious

Robert et al

418 (RCT)

Weber et al

405 (RCT)

Seriousg

Not Serious

Not Serious

Not Serious

None

Ribas et al

655 (RCT)

Serioush

Seriousi

Not Serious

Not Serious

None

Overall
Quality of
Evidence
Very Low
+
Moderate
+++
Very Low
+
Very Low
+
High
++++
Moderate
+++
Low
++

OS = Observational Study RCT = Randomized Controlled Trial
Overall Quality Among All Studies: Low
aAll Observational Studies automatically start at a “low” overall quality of evidence.
bSome of the authors reported being either being employed, having ownership interests in, or receiving funding from Pfizer,
Intrexon, Schering, Vical, Bristol-Myers Squibb, Glaxo, Wyeth, Novartis, Genentech and Johnson & Johnson.
cSome of the authors reported receiving personal fees, grants, holding leadership roles, being employed, and/or providing other
services to Bristol-Myers Squibb, Amgen, Merck, MedImmune, GlaxoSmithKline, Roche, Novartis and Merck Sharp and Dohme.
dSome of the authors reported holding leadership roles and/or receiving funding from Bristol-Myers Squibb, Merck Sharp and
Dohme, Roche-Genentech, GlaxoSmithKline, Amgen, and Celgene.
eStudy had a small population size of 27 patients.
fFour patients were unintentionally enrolled despite having an ECOG status of 2. One additional patient was enrolled without
reporting an ECOG status.
gSome of the authors have reported receiving grants, funding, honoraria, personal fees, holding leadership roles, owning stock
and/or being employees of Bristol-Myers Squibb, Merck Sharp and Dohme, Genentech, Astrazeneca, AbbVie, GlaxoSmithKline,
Macrogenics, Ichor Therapeutics, Lion Biotechnologies, Pierisl, Celldex Therapeutics, Altor BioScience, cCAM Biotherapeutics,
Novartis, Merck Serono, Almirall-Hermal, Leo Pharma, Amgen, Galderma, Janssen, Boehringer Ingelheim, Pfizer, Provectus,
Prometheus, National Comprehensive Cancer Network, Celgen, Genentech, Threshold, Eisai, Roche, Allos, AstraZeneca
MedImmune, Anaeropharma, Merus, Symphogen, Nektar, Kyowa-Kirin, Astellas-Agensys, Amphivena, Neostem, Seattle
Genetics, Immunova, TRM Oncology, Physicians Education Resource, Imedex, Research to Practice, Ventana, Lilly, One author
has a pending patent from Immune Target.
hSome of the authors indicated a financial or other interest relevant to the subject matter. They either held leadership roles,
owned stock, were employed by and received honoraria or research funding from Pfizer, Amgen, Bristol-Myers Squibb,
Genentech, GlaxoSmithKline, Millenium Pharmaceuticals, Novartis, Genta, Merck Sharp and Dohme, Philogen, Roche, SOBI,
Plexikkon, Celgene, Eisai.
iAn unknown number of patients received ipilimumab at other sites when they were only being treated with Tremelimumab as
part of the study.
Kirkwood et al saw the need for new treatment options in patients with metastatic melanoma, as current therapies
including interleukin-2, chemotherapy with dacarbazine or temozolomide and IFN-α2b yield low responses with high
toxicity.10 As such, Kirkwood et al. 10 conducted a multicenter, phase II, single-arm study in order to assess the
objective rate response rate of tremelimumab, a fully human IgG2 monoclonal antibody specific for CTL-associated
antigen 4 (CTLA-4), as well as calculate the safety profile and pharmacokinetics. Kirkwood et al.10 specifically looked at
the best overall response to the drug, while secondary endpoints included safety and tolerability to the drug, durable
response rate, overall survival, duration of tumor response, and progression-free survival. Tremelimumab was
administered using 15 mg/kg every 90 days or 10 mg/kg every month. Tumor assessments were completed at the end
of each cycle and on day 60 of the second cycle. If a tumor response was present after 6 months, this was defined as

a durable response. Patients 18 years and older with surgically incurable Stage III or IV melanoma that was refractory,
or had relapsed after one or more cycle of prior treatment with IL-2, dacarbazine, temozolomide, or IFN-a for
metastatic melanoma were considered eligible. The study consisted of 251 patients between December 2005 and
November 2006. Participants had to meet the above inclusion and exclusion criteria with the addition of having one or
more measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines,
“serum lactate dehydrogenase (LDH) level ≤2 × upper limit of normal (ULN) and adequate bone
marrow, hepatic, and renal function determined within 14 days of enrollment (absolute neutrophil
count ≥1.5 × 109 cells/L, platelets ≥100 × 109 cells/L, hemoglobin ≥10 g/dL, aspartate
aminotransferase and alanine aminotransferase ≤2.5 or ≤5 × ULN with liver metastases, total
bilirubin ≤2 × ULN, and serum creatinine ≤2.0 mg/dL). Additionally, patients were required to have
recovered from all previous treatment-related toxicities to baseline status or to grade 0 or 1
according to National Cancer Institute Common Terminology Criteria for Adverse Events version
3.0.”10
Additionally, patients were excluded if they had previously been treated with any CTLA4-inhibiting agent, had any
treatment for cancer within one month of enrolling into the trial, a history of autoimmune disease, inflammatory bowel
disease, any vaccine therapy for melanoma within six months of enrollment, a potential need for systemic
corticosteroids or concurrent immunosuppressive drugs, brain metastases (unless no longer detectable after previous
treatment), and a history of other malignancies not including basal cell carcinoma, squamous cell carcinoma, or
cervical carcinoma.10
Therapy was discontinued if there was disease progression, or if toxicity occurred and the side-effects were considered
intolerable. After each cycle, a subsequent dose was only administered if the patient had an adequate performance
status, hepatic function, renal function, and acceptable amylase and lipase levels. Additionally, subsequent dosing was
only administered if treatment-related adverse effects were resolved and considered tolerable by the day the dose was
to be administered. Most (77%) of patients developed a treatment-related adverse effect of any grade, however most
were mild-moderate, (grade 1 or 2). Fifty-one (21%) patients developed adverse effects greater than grade 2. Fortyseven (19%) patients had more serious adverse effects. Some of the common adverse effects included nausea,
diarrhea, fatigue, vomiting, and pruritus. Thirteen patients discontinued the study due to treatment-related adverse
effects and two treatment-related deaths occurred. In nine patients, treatment-related endocrine adverse effects
occurred, with eight of these patients obtaining thyroid disorders, and one patient with hypophysitis and pituitary
insufficiency.10
The results of the study by Kirkwood et al revealed that the average overall survival for all participants was 10 months,
while the clinical overall rate, that is, the overall response with stable disease, was 21%.10 All lesions were measured
according to RECIST guidelines. Two-hundred and forty-six patients received at least one dose of tremelimumab. On
average, participants received one dose, while 109 patients (44%) received two or more doses. Sixteen (6.6%)
patients had partial responses, 35 reached a stable disease state (defined as no disease progression for at least 70
days following initial dosing), three achieved responses within the first cycle, and no responders achieved complete
response. All those that responded to treatment sustained the response for at least 170 days after enrollment and as
such, met the criteria for a “durable response.” Eleven patients had ongoing responses at the time of the last tumor
assessment, one patient with a family history of sudden death died of a cardiac event 321 days after enrollment, while
15 patients that responded to treatment are still currently alive with overall safety ranging from 20.1 to 34.1 months.
Eight (3.3%) patients achieved responses in target lesions, despite progressive disease within the first cycle, and all
eight survived for >20 months. Progression-free survival was 15% at six months, 40.3% at 12 months, and 22% at 24
months. Baseline Eastern Cooperative Oncology Group (ECOG) status was the strongest indicator for survival, while
age and sex did not seem to strongly affect survival. The study showed no difference in overall survival between
patients that previously received interferon or previous IL-2, versus those with no prior interferon, contrary to prior
studies, which indicated a significant shorter time to progression in those previously receiving IL-2.10

Table 2. Phase II Trial of Tremelimumab (CP 675,206) in Patients with Advanced Refractory or Relapsed
Melanoma10
Primary
Secondary Endpoints
Endpoint
Overall
response

Duration of tumor
response

Progression free
Safety
survival
15.0%
8.9 to 28.9
Tremelimumab
6.6%
10 months
40.3%
77%
months
22.0%
Progression free survival: patient’s disease reaches a plateau and no longer progresses. Measured 15% at 6 months, 40.3%
at 12 months, 22% at 24 months
Safety: percent of patients who experienced an adverse event. Most adverse events were mild to moderate (grade 1/2).
Grade 3/4 adverse events included diarrhea (11%), fatigue (2%), and colitis (4%).
Overall survival

Eggermont et al conducted a multinational, randomized, double-blind phase III trial evaluating patients with
histologically confirmed melanoma metastatic only to local lymph nodes between July 10, 2008 and Aug 1, 2011.11 The
study primarily looked at recurrence-free survival in patients with primary cutaneous stage III melanoma that had been
completely excised with adequate surgical margins and complete regional lymphadenectomy at least 12 weeks prior to
randomization. Trials were performed in 91 hospitals across 19 countries and consisted of a total of 951 patients who
were randomly assigned to treatment with ipilimumab, a fully human monoclonal antibody that augments anti-tumor
immune responses by blocking CTLA-4, or a placebo. The patient population included those age 18 or older with stage
IIIA, stage IIIB, or stage IIC melanoma with no metastasis present at time of selection into the trial. Patients had to
meet the above inclusion criteria in addition to an Eastern Cooperative Oncology Group: performance status less than
1, with no cardiovascular disease, autoimmune disease, uncontrolled infections, white blood cell count lower than 2.5 ×
109 cells per L, absolute neutrophil count lower than 1.0 × 109 cells per L, platelets lower than 75 × 109 cells per L,
hemoglobin concentration less than 9 g/dL, creatinine higher than 2.5 times the upper normal limit, hepatic enzymes or
lactate dehydrogenase higher than two times the upper normal limit, use of systemic corticosteroids, and previous
systemic therapy for melanoma.11
Random assignments were stratified by disease stage and regions of the world including North America, Europe, and
Australia. The patients received either a placebo or IV infusions of ipilimumab 10 mg/kg every three weeks for four
doses, then every three months for up to a maximum of three years, or until unacceptable toxicity, major protocol
violation, disease recurrence, or the patient refused treatment. The initial four doses were considered induction doses,
additional doses thereafter were considered maintenance doses and were added based on principles of re-stimulation
of the immune system.11
The result of the Eggermont et al study showed that the median recurrence-free survival was appreciably longer in the
ipilimumab group at 26.1 months versus the placebo group at 17.1 months.11 Three-year survival was also expectedly
longer for the ipilimumab group at 46.5% versus the 34.8% in the placebo group. In those with stage IIIC disease,
ipilimumab’s effect was the most evident. The average number of doses received per patient was four in the
ipilimumab group and eight in the placebo group. The primary goal of the study was recurrence-free survival which was
defined as the time between the date of randomization and the date of initial recurrence or death. "Of 471 patients who
started ipilimumab, 245 (52%) discontinued treatment because of an adverse event, of which 230 (49%) were drug
related; in 182 (39%) patients the adverse event leading to discontinuation happened within 12 weeks of the start of
treatment."11 The most common adverse effects were gastrointestinal, hepatic, and endocrine, in which most patients
had only one serious episodic event. In the ipilimumab group, a total of five patients died due to drug-related adverse
effects including one due to myocarditis, one due to multi-organ failure with Guillain-Barre syndrome, and three
patients died due to colitis. There were no deaths related directly to treatment in the placebo group. As a whole, the
authors found that the drug, ipilimumab, showed a significantly increased recurrence-free survival in patients with highrisk stage III melanoma that had been completely resected.11

Table 3. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma11
Primary
Endpoint
Recurrence free
survival

Secondary Endpoints
Distant metastasis
free survival

Overall survival

Adverse event
profile

Ipilimumab
26.1
p
p
99%
Placebo
17.1
p
p
91%
Recurrence free survival: patients still alive after start of treatment and without disease
Distant metastasis free survival: patients still alive after start of treatment without distant metastasis
Adverse event: any mild to severe side effect that occurred after the start of the study
*p=pending

Health related
quality of life
p
p

Altomonte et al conducted a randomized controlled phase III trial involving ipilimumab. Researchers used data from an
expanded access program in Italy.12 The program evaluated clinical activity and safety of the monoclonal antibody in
patients with advanced melanoma disease in a daily practice setting. Clinical activity and safety profile of ipilimumab
was evaluated in patients older than 16 years of age with advanced melanoma in a setting similar to daily practice.
Patients were eligible for participation in the expanded access program if they had histologically confirmed
unresectable stage III/ IV skin, ocular, or mucosal melanoma. Patients had to previously fail systemic therapy, been
intolerant to more than 1 systemic therapy, or have no other therapeutic options available. Eastern Cooperative
Oncology Group (ECOG) performance status of 0, 1, or 2 was required, and at least 28 days since previous treatment
with chemotherapy, biochemotherapy, surgery, radiation, or immunotherapy was recommended. Patients with
asymptomatic brain metastases were included. Exclusion criteria included any other systemic therapy for the treatment
of melanoma, concomitant autoimmune diseases or other malignancies, and known HIV, hepatitis B or C infection.12
Treatment in this study comprised ipilimumab 10 mg/kg every three weeks for a total of four doses. Maintenance
therapy was provided every 12 weeks, if patients would continue to benefit from the treatment. Tumor responses were
assessed every 12 weeks using modified World Health Organization (WHO) criteria. Seventy-four pretreated patients
with advanced melanoma were treated with ipilimumab 10 mg/kg. Of these patients, 43 (58.1%) received all 4
induction doses, 14 (18.9%) received three doses, five (6.8%) received two doses and 12 (16.2%) received only one
dose. Reasons of incomplete treatment regimens include: disease progression (n=13), death due to disease
progression (n=10), loss to follow up (n=5), drug toxicity (n=2) and other unknown causes (n=1). Twenty-six patients
receive maintenance therapy with ipilimumab. Patients who did not receive maintenance therapy did so for the
following reasons: disease progression (n=30), death due to progression (n=9), loss to follow-up (n=5), toxicity (n=2),
grade II nausea and diarrhea (n=1), and grade I diarrhea (n=1). Of the 74 patients who started the trial, 69 were
evaluated for tumor response. At week 12 of treatment, six patients had an objective response (8.7%). At greater than
12 weeks, nine out of the 74 pretreated patients (13.0%) had an objective tumor response, with three patients having a
complete response and six having a partial response. Twenty-two patients, (31.9%) gained disease control as defined
by stable disease lasting for at least 24 weeks following the first dose of ipilimumab, complete response to treatment or
partial response to treatment. Median overall survival of the total patients totaled to about 7.0 months (95% confidence
interval, 5.3–8.7) and 16.6% of patients remained living after three years. 45 patients (60.8%) claimed that they
experienced adverse effects related to the treatment overall. Side effects included low-grade pruritus, pain, fever and
diarrhea (grade I and II). Higher-grade related side effects were reported in only eight patients (10.8%). One patient
reported fever, epigastric pain, elevated AST and pancytopenia which was resolved with discontinuation of ipilimumab
and use of immunosuppressive therapy, immunoglobulins and supportive therapy.12

Table 4. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part
of a European expanded access programme12
Measurements*
Objective
response

Disease Control

Overall survival

Adverse event
profile

Progression free
survival

Ipilimumab
13.0
31.9%
7 months
60.8%
3 months
*Note: primary and secondary endpoints were not defined in this study
Objective response: any positive response to treatment after 12 weeks, of the 13% of patients: 4.3% had a complete
response and 8.7% had a partial response.
Disease Control: stable disease lasting for at least 24 weeks following the first dose of ipilimumab, with complete response to
treatment or partial response to treatment.
Adverse event: any mild to severe side effect that occurred after the start of the study. Most commonly grade 1/2 including
low-grade pruritus, pain, fever, and diarrhea. Only 10.8% were Grade 3/4 adverse events.
Progression-free survival: patient’s disease reaches a plateau and no longer progresses.
Di Giacomo et al completed a similar study involving ipilimumab that aimed to evaluate the feasibility of the monoclonal
antibody in the treatment of metastatic melanoma in a setting similar to daily practice.13 The monoclonal antibody was
utilized in an expanded access program only for patients with life-threatening, unresectable stage III/IV skin, ocular, or
mucosal melanoma who had failed prior treatments with chemotherapy or for patients who did not have any other
treatment options available. Patients with brain metastases were also allowed to be included in the study. Additionally,
an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 was required. This study also recommended
at least 28 days of absence from chemotherapy, biochemotherapy, surgery, radiation, and immunotherapy. Exclusion
criteria involved any other systemic therapy for melanoma, concomitant autoimmune diseases or other malignancies,
and any known HIV or Hepatitis B or C infection.13
Treatment in this study included four doses of 10 mg/kg ipilimumab administered intravenously every eight weeks.
Maintenance doses were provided every 12 weeks if needed. Tumors were assessed at baseline, week 12, and every
12 weeks according to WHO tumor response criteria. Disease control was defined as stable disease lasting for at least
24 weeks following the first dose of ipilimumab, complete response to treatment or partial response to treatment.
Disease control rates were analyzed at 24 and 60 weeks. The rates were 29.6% at week 24 and 15% at week 60.
Median follow up was performed at 8.5 months and the overall survival rate was found to be nine months. Survival
rates were established after one year (34.8%) and two years (23.5%). During ipilimumab treatment, lymphocyte counts
greater than 1500 cells/μL correlated with increased overall survival (41 weeks overall survival) versus patients with
lymphocyte counts less than 1500 cells/μL (21 weeks overall survival).13
Patients receiving treatment experienced immune-related side effects that were easily managed and sometimes
reversed under special circumstances. Immune-related adverse events consisted mainly of rash, pruritus, fever and
diarrhea and were mainly grade 1 or 2, except for two patients which experienced grade 3 diarrhea that was reversed
with antidiarrheals and corticosteroids. Two patients did not complete treatment. One was due to progression of
disease and the other case was due to diarrhea upon restarting ipilimumab. One patient had a grade 3 adverse event
consisting of elevated ALT/AST that resolved with steroids and allowed the patient to restart maintenance. One grade
4 adverse event related to the drug was central pancytopenia during the maintenance phase which led to
discontinuation of ipilimumab; this condition was irreversible despite management resulting in death. This patient also
had very rapid disease progression with metastases to the brain, lungs and soft tissue, which possibly contributed to
their exiting the study.13

Table 5. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the
University Hospital of Siena (Italy).13
Measurements
Duration of tumor
Disease Control
Overall survival
Adverse event profile
response
Ipilimumab
7.3-32 mos
29.6%
9.6 months
65%
Note: primary and secondary endpoints were not defined in this study
Disease Control: stable disease lasting for at least 24 weeks following the first dose of ipilimumab, with complete response to
treatment or partial response to treatment.
Adverse event: any mild to severe side effect that occurred after the start of the study. Most common were grade ½ immune
related events including pruritus, fever, diarrhea. Two patients experienced grade 3 diarrhea, One patient with two week
elevation of AST/ALT liver enzymes. One patient experienced grade 4 pancytopenia.
Robert et al conducted a phase III controlled study in which they assessed the use of nivolumab, compared to
chemotherapy, in treating patients with ipilimumab-refractory metastatic melanoma.14 The inclusion criteria were
patients of 18 years or more with confirmed, metastatic, stage III/IV melanoma without a BRAF mutation that has not
been treated in the past, and available tissue from the unresectable site. The exclusion criteria included metastases of
the brain, uveal melanoma, previous melanoma treatment, and history of autoimmune disease. After randomization,
there were 210 patients in the nivolumab group and 208 participants in the dacarbazine group. During database lock,
46.1% of patients receiving nivolumab and 6.3% of patients receiving dacarbazine were involved in the study. Patients
in the nivolumab group received 3 mg/kg every two weeks along with a dacarbazine-matched placebo every three
weeks, while patients in the chemotherapy group got 1000 mg of dacarbazine per square meter of body-surface area
every three weeks along with nivolumab-matched placebo every two weeks. Treatment was provided until the disease
progressed or produced a toxic effect. In this study, the Response Evaluation Criteria in Solid Tumors (RECIST) was
used to grade tumor response. The primary endpoint was overall survival. Progression-free survival was assessed and
determined per the investigator’s judgment.
The average length of median overall survival was reported to be 10.8 months for patients treated with dacarbazine;
the median overall survival for patients treated with nivolumab was not reached because the overall survival rate for
said group was always more than 50% during the course of the entire study. The rate of overall survival after one year
in the nivolumab group was 72.9%, compared to 42.1% in the chemotherapy group. The average survival time without
progression in patients treated with nivolumab was 5.1 months and 2.2 months in those treated with dacarbazine.
Patients in the nivolumab group achieved an objective response rate of 40%, while those in the dacarbazine group
achieved only 13.9%. Complete responses were noted more in the study group compared to the chemotherapy group.
In the nivolumab group, a reduction in tumor burden of at least 30% was achieved after progression of disease in 8.1%
of patients. In the dacarbazine group, a reduction in tumor burden of at least 30% was achieved after progression of
disease in only 3.8% of patients.14
The subgroups in this study were determined by PD-LI status, negative or positive, assessed through an
immunohistochemical assay, which was not relevant in establishing overall survival. If 5% or more of tumor cells
demonstrated cell-surface PD-L1 staining in at least 100 cancer cells, then it was considered to be PD-L1 positive.
Within the nivolumab group, neither the positive nor negative PD-L1 subgroup attained median overall survival. With
dacarbazine, the average overall survival in the positive PD-L1 subgroup was a little longer. Both subgroups treated
with nivolumab had better objective response rates than patients treated with dacarbazine. 14
There was not a significant difference in adverse events between the experimental group and the control group,
although patients in the nivolumab group presented with lesser grade 3-4 adverse events such as diarrhea and
increased percentage of alanine aminotransferase. The most common side-effects in the nivolumab group were
fatigue, pruritus and nausea, while in the dacarbazine group, they were gastrointestinal and hematological toxicity.
There were no deaths related to either study treatment.14

Table 6. Nivolumab in previously untreated melanoma without BRAF mutation. 14
Primary Endpoint

Secondary Endpoints

Overall survival
Progression free survival
Objective Response rate
Nivolumab
72.9%
5.1 mos
40%
Placebo
42.1%
2.2 mos
13.9%
Progression free survival: patient’s disease reaches a plateau and no longer progresses.
Objective response rate: the percentage of patients who had some type of positive response to treatment, including both
complete and partial responses
The randomized, controlled, phase III study conducted by Weber et al compares the role of nivolumab versus
investigator’s choice of chemotherapy (ICC), either dacarbazine, paclitaxel or carboplatin, in treating patients who have
progressed with advanced melanoma following anti-CTLA-4 treatment, specifically ipilimumab or ipilimumab and a
BRAF inhibitor.15 The study involved 272 patients in the nivolumab group and 133 in the ICC group after
randomization. The inclusion criteria were age of at least 18 years, confirmed, stage IIIC or IV metastatic melanoma,
and in patients with BRAF mutation, disease progression following anti-CTLA-4 treatment and a BRAF inhibitor. The
exclusion criteria were metastases of the brain, prior treatment with anti-PD-1 and its ligands, or primary ocular
melanoma. Due to not being able to meet study criteria and consent withdrawal, four patients receiving nivolumab and
31 patients receiving ICC were excluded. From the remaining population, those who were qualified for primary
assessment of objective response were 120 patients in the study group and 47 in the ICC group. The researchers used
RECIST version 1.1 to assess tumor responses.15
After treating patients with nivolumab per-protocol for 5.3 months on average, the investigators noted that the median
follow-up time of those who attained an objective response was 8.4 months. The principal goal of objective response
was achieved in 38 patients in the nivolumab group compared to five in the ICC group. The average length of response
was 3.5 months in the ICC group, while it was not reached in the study group. The median time to produce a response
with nivolumab was 2.1 months, compared to 3.5 months in the control group. Of the 38 patients who had objective
responses with nivolumab, 33 were able to endure treatment without disease advancement. Thirty-one percent of 120
patients in the nivolumab group were able to sustain treatment regardless of progression, which was defined as more
than 30% decrease in the target lesion after initial progression; moreover, 8% had a one-third decrease in the length of
marked lesions. The progression-free survival at six months for patients treated with nivolumab was 48% and for those
treated with ICC was 34%.15 When examining subgroups determined by BRAF status, previous anti-CTLA-4 benefit, or
PD-L1 status, it was found that there were more responses, whether complete or partial, in the study group compared
to ICC group.
Adverse events occurred in 68% of patients in the study group, with the most common being fatigue, itching, and
diarrhea, and in 79% of patients in the control group, with nausea, fatigue, and hair loss being the most common.
Treatment-related and drug-related grade 3-4 adverse events such as fatigue, anemia, vomiting, and neutropenia were
noticed more in the ICC group than in the nivolumab group. Although there were grade 3-4 select adverse events in
the nivolumab group, they were reversed by delaying the next dose and using immunosuppressive medicines. Due to
the progression of melanoma, 43% of nivolumab patients and 61% of ICC patients had to stop treatment. Another
reason for ending treatment was drug toxicity, and it affected a small portion of patients in both groups. There were no
reported deaths linked to the study treatments.15

Table 7. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4
treatment15
Primary Endpoint

Secondary Endpoints

PDL-1 status
Progression free
survival
Positive
Negative
Nivolumab
12.3 mos
31.7%
4.7 mos
77%
87%
Placebo
8 mos
10.6%
4.2 mos
9.1%
13%
Objective response: any positive response to treatment after the start of the study
Progression free survival: patient’s disease reaches a plateau and no longer progresses.
PDL-1 Status: an objective biomarker expressed in the tumor, which was used to predict overall survival
Overall Survival

Objective Response

Ribas et al performed a randomized clinical trial including 655 treatment-naive patients with unresectable stage IIIC or
IV melanoma to assess overall survival, duration of response, safety, as well as progression-free response in patients
treated with the monoclonal antibody tremelimumab versus standard chemotherapies temozolomide or dacarbazine.16
Progression-free survival (PFS) is defined as the time during and after treatment when the disease reaches a plateau
and does not progress. In this study, progression-free survival was assessed at six months. The inclusion criteria were
patients 18 years and older with unresectable stage IIIC or IV metastatic melanoma with no prior history of treatment,
an Eastern Cooperative Oncology Group performance status of ≤ 1, serum lactate dehydrogenase of ≤ 2x the upper
limit of normal, and adequate renal, hepatic and bone marrow function. Exclusion criteria included patients with brain
metastasis or uvula melanoma. In this study, RECIST guidelines were used to evaluate tumor response.
There were a total of 655 patients randomly assigned to the control arm with standard chemotherapy or to the new
monoclonal antibody tremelimumab. Patients treated with tremelimumab were administered a 15 mg/kg dose via
intravenous infusion once every 90 days. While patients on dacarbazine were administered 1,000 mg/m 2 via
intravenous infusion once every 21 days or temozolomide 200 mg/m2 orally on days one through five of a 28 day
cycle.16 Patients treated with the monoclonal antibody were assessed every 90 days and patients on dacarbazine or
temozolomide were assessed every 42 days and 56 days. The average duration of treatment was two to three months.
The objective response rate was 10.7% in the tremelimumab arm and 9.8% in the standard chemotherapy arm.16
Median response duration to treatment was much longer for tremelimumab at 35.8 months versus standard
chemotherapy at 13.7 months. After treatment, two- and three-year survival rates were 26.4% and 20.7% for
tremelimumab and 22.7% and 17.0% in patients treated with traditional chemotherapies. Three years after the start of
the study, in the final study analysis, median overall survival was 12.6 months for tremelimumab and 10.7 months in
the chemotherapy arm. In phase I and II trials, tremelimumab showed longer responses in a portion of the patients with
advanced stage melanoma. However, the phase III study, which focused on the overall survival rate and efficacy of
tremelimumab, failed to provide an increased survival advantage over treatment with standard-care chemotherapy.
The main side effects noted for tremelimumab included diarrhea, pruritus and rash, yet a small percentage of patients
reported more severe side effects including thyroid, hypothalamic or pituitary gland disorders, and adrenal
insufficiency.16 For the two conventional chemotherapeutic agents, temozolomide or dacarbazine, the most common
reported side effects were nausea/vomiting, constipation, and fatigue. Seven treatment-related deaths were recorded
for the monoclonal antibody, whereas only one death was recorded in the treatment with standard of care
chemotherapies dacarbazine or temozolomide.

Table 8. Phase III randomized clinical trial comparing tremelimumab with standard of care chemotherapy in
patients with advanced melanoma16
Primary
Endpoint
Overall
survival
12.6 months

Secondary Endpoints
Progression free
survival
20.3%

Best overall
response
10.7%

Duration of
response
35.8 months

Safety

Tremelimumab
85%
Chemotherapy
(Dacarbazine or
10.7 months
18.1%
9.8%
13.7 months
28%
Temozolomide)
Progression free survival (OS): patient’s disease reaches a plateau and no longer progresses. Measured at six months after
the start of treatment.
Safety (S): percent of patients who experienced an adverse event. Most adverse events were mild grade 1/2 including
diarrhea, pruritus, and rash. Grade 3/4 adverse events related to tremelimumab included diarrhea (14%) and endocrine
events (7%) such as thyroid or hormone effects. Grade 3/4 adverse events related to chemotherapy included neutropenia
(10%) and thrombocytopenia (2%).
DISCUSSION
The primary goal of the study conducted by Kirkwood et al was to find the best overall response.10 The responses to
tremelimumab were considered durable, in that, all patients that had an objective response also sustained their
response for more than 170 days after enrollment into the study. As such, tremelimumab has shown durable clinical
activity in second-line treatment of patients with surgically-incurable stage III or IV melanoma, suggesting a potential
role for tremelimumab in melanoma. Moreover, the study found that an increase in lactate dehydrogenase does not
bias against response to therapy, as had been suggested for chemotherapy, and as such, the exclusion of patients
from trials based on elevations in LDH does not seem to be appropriate. Analysis of antitumor responses in the study
also do not support the current assumption that immunotherapy only benefits the healthiest of patients, while only
causing a burden to those with minimal disease. Additionally, it is important to note that Pfizer funded this study’s
medical editorial assistance and there is a likelihood of publication bias.
Adverse effects of tremelimumab must also be considered, as most (77%) of the patients developed a treatmentrelated adverse effect, with most of the effects being mild to moderate. Only 5% of patients discontinued the trial due to
treatment-related adverse effects, and only two (0.8%) treatment-related deaths occurred.10
More studies must be performed in order to identify the specific patient population which will respond to tremelimumab,
and to determine the early indicators for later response to therapy, thus improving the therapeutic index and allowing
for other agents or combinations for those who fail to respond to tremelimumab. Currently, studies using combinations
of tremelimumab with vaccines and with IFN-α are in progress.10
The study conducted by Eggermont et al showed significantly increased recurrence-free survival with use of ipilimumab
in patients with completely resected high-risk stage III melanoma.11 Recurrence-free survival was determined by
calculating the amount of time between the date of randomization and either first recurrence of disease or death,
whichever occurred first. Based on a phase II trial, the dose of 10 mg/kg was chosen, as it had shown the best results,
however, this dose was markedly higher than the approved dose of 3 mg/kg for treatment of patients with advanced
melanoma. In the EORTC 18991 trial, adjuvant pegylated interferon was compared to observation. This study showed
the importance of studying microscopic versus macroscopic nodal involvement, as well as the presence or absence of
ulceration of the primary melanoma. It was suggested that lymph nodes with tumors of microscopic size may have a
greater benefit than patients with larger palpable lymph nodes. Similarly, in Eggermont et al’s study, ipilimumab
showed that this held true, however, there was still a substantial benefit in the patients with palpable nodes as well as
patients with ulcerated melanoma. In addition, interferon also had a substantial effect on patients with nodal
involvement. As such, it was noted that ulcerated melanoma is a “separate biological entity”.11 Additionally, it is
important to note that Bristol-Myers Squibb, GlaxoSmithKline, Roche, Merck, and Agmen served on the advisory board
and funded this study, increasing the likelihood of bias.

The adverse effect profile for ipilimumab must also be considered, as nearly 40% of the patients discontinued
treatment before the completion of the initial dosing period, that is, before the maintenance period; the reason behind
this remains to be investigated. While knowing if this high adverse effect profile is due to longer drug exposure or
greater sensitivity remains speculative, in a pooled analysis of studies using a dose of 10 mg/kg in patients with
advanced melanoma, most immune-related manifestations resolved within four to six weeks. The drug-related fatalities
were also alarming. Although great care was taken to monitor the patients closely in addition to meticulous instruction
of the patients, 1% of the patient population in the study died, due to drug-related causes after discontinuing
ipilimumab.11 It is unknown if the treatment-related deaths could have been prevented if the complications had been
managed differently.
The definitive value of distant metastasis-free survival and overall survival endpoints have yet to be defined, and the
risk-benefit ratio of adjuvant ipilimumab at the dose tested requires further evaluation. Additional studies must also be
performed to provide additional insight on the benefits of higher dose ipilimumab versus the standard dose used for
unresectable metastatic disease, and to discover if either dose of ipilimumab truly improves outcomes or is less toxic
than high-dose interferon.11
The clinical studies involving ipilimumab 10 mg/kg in patients with melanoma used data from programs at Italian
centers known as an expanded access programs. Altomonte et al and Di Giacomo et al evaluated clinical activity and
safety of the monoclonal antibody in patients with advanced melanoma disease and pretreated patients with advanced
disease in a daily practice setting.12,13 This type of study was important to include because it is more indicative of
ipilimumab safety and efficacy in the typical setting for day-to-day patients and not just within the parameters of clinical
trials.
After thorough analysis of heavily pretreated patients with advanced melanoma, Altomonte et al concluded that the
expanded access program suggested that the clinical activity and safety profile of ipilimumab was actually similar to the
results found in clinical trials.12 The author states that the safety profile, adverse effects, tumor assessment and
response, and overall survival rates were actually consistent with the results reported in previous phase II and III
clinical trials.12
Most adverse events were consistent with previous trials and consisted mainly of dermatological and gastrointestinal
occurrences. Sixty-one percent of patients experienced adverse effects related to their treatment, but no deaths were
related to their therapy. Interestingly, there was a decrease in the amount of reported high-grade adverse, events
which the authors believe may have been due to the “retrospective” nature of this study. They also point out that there
is a decrease in the requirement for intervention in incidents of bowel perforation, which may be due in large part to
better management and the advent of more clear algorithms for proper management. Overall, the use of established
algorithms for the proper management of adverse events and the ability to anticipate specific side effects of ipilimumab
has led to a more manageable safety profile, which demonstrates that ipilimumab may be safely administered and
managed by community-based physicians in a daily clinical setting.12
An assessment of tumor response rates at week 12 demonstrated a 9% objective response. Altomonte et al note that
beyond week 12 an increase in the number of patients that achieved an objective response was observed, possibly
due to the fact that the body requires time for the immune response to affect tumor size after stimulation by monoclonal
antibodies.12 Overall survival was observed to be seven months. The median survival rates for other clinical trials have
been shown to be approximately 10 months, which is different from the seven months median overall survival observed
in this study. The authors note that it is important to take into consideration that the patients who participated in this
study had a very poor prognosis and significantly advanced disease as classified by their M status which defines
severity with respect to metastasis.12 Other studies have highlighted poor performance status, visceral disease, brain
metastases, and M status as factors that have a statistically significant effect on prognosis. At least two years of
survival was observed by one-fifth of patients with approximately 17% of patients alive at three years. Although this
study proved the efficacy of ipilimumab in treating patients with melanoma, more studies are needed to establish the
proper dose for maximum treatment benefit. The expanded access program for this study was sponsored by BristolMyers Squibb. Additional funds were provided to support editorial and writing assistance by StemScientific through the
Bristol-Myers Squibb company.12
Di Giacomo et al also found ipilimumab to be a viable treatment option for malignant melanoma in previously-treated
patients experiencing a progression of their disease.13 The expanded access program showed that a large number of

the patient population benefited from the treatment and resulted in long-term survival similar to that observed in phase
II clinical trials. It is of note that this study has a small sample size of 27 patients, which limits it applicability to clinical
use. Two case studies were included within this article, however their findings were not specifically reported since case
studies were excluded in our analysis.13
Objective responses with disease control was achieved in 22% of patients with a median overall survival of 9.6 months,
one year survival rate of 34.8% and two year survival rate of 23.5%. In addition, the safety profile of ipilimumab in this
program was found to be substantially similar to that seen in previous phase II and III clinical trials. Treatment was
associated with generally mild immune or mechanism-related side effects that were manageable and reversible in most
cases, which also parallels similar results in clinical trials. These findings are important and helpful for community
physicians using ipilimumab in daily practice, since it illustrates that following management protocols for these adverse
events facilitates the use of monoclonal antibodies for this indication. The author suggests that strict adherence to this
treatment protocol with this monoclonal antibody will provide a strong contribution to allow safe use of this agent in
daily clinical practice.13
Furthermore, a sizeable proportion of the patients in the expanded access program experienced a durable clinical
response, including benefits to long-term survival. Disease control with ipilimumab also followed a pattern slightly
different than that seen with chemotherapy. It was observed that disease control may be delayed or can be seen
following further treatment after disease progression, posing the possibility that continued treatment may benefit
patients with stable or progressive disease. Di Giacomo et al also mention that a unique immune-related response
criteria to evaluate clinical response may be a more adequate method of evaluating tumor response than WHO or
RECIST criteria.13 With these observations and conclusions, patients and treating physicians will have a greater
awareness of the clinical response patterns and side effects related to ipilimumab.13
This study received editorial and writing assistance from StemScientific funded by Bristol-Myers Squibb company.
Through this support, the expanded access program was able to provide evidence to show that ipilimumab is an
effective and safe treatment option to use in daily practice for metastatic melanoma. These clinical responses also
show that, even with failed prior treatment options, disease progression can be stopped with this monoclonal
antibody.13
The results of the experiment performed by Robert et al indicate that an overall survival rate was attained more in
patients treated with nivolumab compared to those treated with dacarbazine.14 Death risk for patients in the nivolumab
group was lowered by 58%.14 The benefit of survival was steady among all subgroups. The survival rate at one year in
the nivolumab group is greater than that in the dacarbazine group, and is in accordance with previous study results.
The reason behind choosing dacarbazine as the chemotherapy drug was that, until recent times, it was the primary
treatment option for those with melanoma void of BRAF mutation. A greater median survival of 10.8 months was noted
in the dacarbazine group, most probably due to the fact that ipilimumab was given to 38% of patients in this group
following cessation of the study treatment. The response to treatment was higher in the nivolumab group with 16
patients achieving complete responses, 68 partial responses and 35 stable disease, compared to two complete
responses, 27 partial responses, and 46 stable disease in the ICC group.
From the current research, it was found that a long-lasting, fast, and an increased rate of response was achieved in
those who were given nivolumab. All these results regarding nivolumab are consistent with previous research which
has shown similar clinical effects, irrespective of BRAF mutation type. Furthermore, as noted in preceding trials, the
safety profile was good and the number of toxic effects were minimal. When choosing patients for therapy with
nivolumab, the status of PD-L1 by itself does not appear to be helpful, and therefore its role in prognosis needs to be
understood in future research. The funds needed for this study were distributed by Bristol-Myers Squibb
pharmaceutical company.14
The study done by Weber et al found that more patients treated with nivolumab, an anti-PD-1 antibody, had complete
objective responses compared to those treated with ICC.15 However, a major variation in survival without progression
was not statistically identified, most probably due to “the imbalance in distribution of adverse prognostic factors in favor
of the ICC group, immaturity of the data, and the false-positive disease progression in the nivolumab group.”15 In the
nivolumab group there were four complete responses, 34 partial responses, and 28 patients with stable disease
compared to the ICC group with zero complete responses, five partial responses, and 16 stable disease. The data and
results achieved with nivolumab in the present experiment are in agreement with preceding trials. Nivolumab has been

accepted by the United States Food and Drug Administration for patients who have disease advancement following
ipilimumab due to prolonged responses. The result of lowered tumor development past RECIST 1.1-defined
progression in 8.3% of patients in the nivolumab group indicates that nivolumab might have a higher potential for
benefit, and could be the reason why there was not a noteworthy difference in survival without progression. Regardless
of the type of BRAF mutation, nivolumab has been found to be effective as noted in previous studies.15
One drawback to this study lies in the analysis of data, where it was noted that 22 patients in the ICC group withdrew
consent, while only one patient in the study-drug group withdrew consent. The authors discussed that this large
number of withdrawals in the control group may have been due to patients seeking alternative, more advanced
treatments, such as other monoclonal antibodies. These patients may have been well-informed regarding the advent of
monoclonal antibodies and had resources affording them this option. The authors attribute the underlying reason for
this to be that the study was not an open-label, non-crossover study design. Even though using immune-related
response criteria could have produced better results in this study, this criteria is not verified by regulatory agencies,
and therefore could not be utilized. It was noted that there was more general safety with nivolumab compared to
chemotherapy, and adverse effects were controlled by drugs and dosage changes. This study was also funded by the
Bristol-Myers Squibb company. The authors who held leadership roles during this research were Jeffrey S Weber, and
James Larkin.15
Overall results in Ribas et al’s study comparing the monoclonal antibody tremelimumab to standard chemotherapy with
dacarbazine or temozolomide concluded tremelimumab was minimally effective in overall survival.16 Tumor response
rates to treatment showed similar progression in reduction of size. Since the duration of responses were significantly
improved, the trial confirms the benefit from treatment with tremelimumab in a certain subset of patients.
The results of this study are further unsupported due to the recent change in the standard of care for melanoma. Now,
the traditional chemotherapy drugs are less commonly used and other new monoclonal antibodies such as ipilimumab
and the BRAF inhibitor, vemurafenib, have been approved for use. In a single-arm phase II study of ipilimumab at 10
mg/kg every three weeks, proved to demonstrate similar efficacy to the tremelimumab phase II trial. Furthermore,
patients with previously-treated melanoma had a greater overall survival when treated with a lower monthly dose of
ipilimumab as opposed to monotherapy with the gp100 vaccine. Additionally, a phase III clinical trial of ipilimumab
recognized the enhanced efficacy of combination therapy (ipilimumab + dacarbazine) versus monotherapy (ipilimumab)
in patients with metastatic melanoma.
The authors also recognize the possibility of patient selection enriching tumor responses and improved outcomes in
the control arm, which decreased the survival difference between treatments with tremelimumab in comparison to
chemotherapy. Also of noteworthy mention in this study, is the exclusion of patients with serum lactate dehydrogenase
≤ 2, as similar studies did not have this exclusion factor. During the course of this study, the drug of choice for
advanced melanoma changed. Consequently, some patients in the control arm who were under treatment with
dacarbazine or temozolomide chose to enroll in concurrent studies, where they were given add-on therapy with the
monoclonal antibody ipilimumab. Five patients admitted to enrolling into this dual therapy; however, Ribas et al
recognizes that this is probably an underestimate of the number of patients who enrolled in additional treatment with
ipilimumab.
Several other inconsistencies in this study may suggest unreliable results. One confounding variable includes the
reduced number of original patients in each phase of the trial. Eight months after the start of the study, 340 deaths had
occurred secondary to metastasis of patients’ advanced melanoma. Two years later, 534 total deaths had occurred
which was 82% of the original population deceased. This left only 131 participants to follow through the end of the
study. Additionally, at the start of the study, one inclusion criteria for patients was a serum lactate dehydrogenase level
≤ 2x the upper limit of normal with adequate bone marrow, hepatic, and renal function. When the study began, it was
noted about 5% of patients had > 2x upper limit of normal for LDH. The variability in route of administration as well as
dose and duration of treatment varied between both the monoclonal antibody and standard of care chemotherapy, but
also between dacarbazine and temozolomide, making it hard to compare the therapies. Due to these differences in
treatment outcomes, further studies need to be performed before adequate conclusions can be obtained. Funding for
this study was provided by several large scale pharmaceutical companies including Bristol-Myers Squibb, Pfizer,
GlaxoSmithKline, Genta, MSD, Synta, SOBI, Novartis, and Roche; all of which may result in unintentional biases.
Additionally, the main leadership roles in this study were all held by individuals employed by Pfizer including Margaret
Marshall, Jesus Gomez-Navarro, Bo Huang, and Dmitri Pavlov.

CONCLUSION
Melanoma is a serious condition that requires research of modern therapy agents to help improve patient’s quality of
life during treatment and prognosis. In this paper, various studies that analyze the safety and efficacy of monoclonal
antibodies, which have recently been upgraded as first-line for the treatment of melanoma, were evaluated. As
previously mentioned, chemotherapy and immunotherapy consisting of IL-2 was first-line, but due to its side effect
profile and inadequate efficacy, monoclonal antibodies are now being used as first-line treatment. The goal of this
paper was to validate the use of monoclonal antibodies as first line treatment.
Of the seven studies evaluated, six demonstrated that monoclonal antibodies do have a prominent role in the treatment
for advanced-stage melanoma. Three studies directly compared the use of monoclonal antibodies to chemotherapy.
The studies conducted by Robert et al and Weber et al showed a statistically significant advantage of monoclonal
antibodies over chemotherapy. The third study conducted by Ribas et al failed to demonstrate a statistically significant
survival advantage over chemotherapy.
It is noteworthy that inconsistencies existed among the primary and secondary endpoints evaluated in each study,
which may affect the overall interpretation of data. And, although each study had similar inclusion and exclusion
criteria, variation among criteria did exist. For example, non-metastatic vs. metastatic inclusion/exclusion criteria and
the use of previous systemic therapy with other therapeutic agents varied among each study. Regardless of these
inconsistencies, the studies demonstrated monoclonal antibodies remained efficacious.
Another inconsistency is the method the various studies used to evaluate tumor response. RECIST and WHO were the
primary modalities used to measure tumor response. Monoclonal antibodies have a mechanism of action which differs
from most other systemic treatment used to treat tumors. Monoclonal antibodies work by eliciting an immune response
from the patient’s body, which is directed to kill the tumor cell. RECIST and WHO were not developed to evaluate
tumor response to this mechanism. Therefore, when evaluated using these methods, monoclonal antibodies may not
have the chance to show their true response, especially when using these methods to compare them directly to
chemotherapy. Methods to evaluate immune-related tumor response are currently being developed, but none have
been evaluated by regulatory agencies and are therefore not used in these studies. 15
All seven studies demonstrated that monoclonal antibodies have a manageable adverse event profile, especially when
compared to previously used immunotherapies. Grade I and II adverse events make up the majority of side effects
seen in all seven studies, most commonly fatigue, pruritus nausea and diarrhea. Kirkwood et al10 had two patient
(0.8%) deaths, Eggermont et al had five patients (1%) deaths and Ribas et al had seven patient deaths directly related
to treatment with monoclonal antibodies. Di Giacomo et al reported one patient death categorized as possibly related
to the treatment with monoclonal antibodies; however, this patient had further metastasis and other comorbidities.
Ribas et al also reported one death directly related to treatment with chemotherapy. When directly compared to
chemotherapy, the monoclonal antibodies had a better adverse event profile.14-16 The studies conducted by Altomonte
et al and Di Giacomo et al showed that the adverse event profile of monoclonal antibodies can be managed using
proper treatment algorithms at typical treatment centers and does not require the use of special facilities and
physicians even with patients with more advanced disease and comorbidities.
Further investigation is warranted to determine which of the monoclonal antibodies is best for the treatment of
melanoma and how combination therapy of multiple monoclonal antibodies, concurrent chemotherapy, vaccines, and
enzyme inhibitors affect treatment outcomes.
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